IL146113A0 - Liposome compositions for improved drug retention - Google Patents

Liposome compositions for improved drug retention

Info

Publication number
IL146113A0
IL146113A0 IL14611300A IL14611300A IL146113A0 IL 146113 A0 IL146113 A0 IL 146113A0 IL 14611300 A IL14611300 A IL 14611300A IL 14611300 A IL14611300 A IL 14611300A IL 146113 A0 IL146113 A0 IL 146113A0
Authority
IL
Israel
Prior art keywords
liposome compositions
improved drug
drug retention
liposomes
fluoroquinolone
Prior art date
Application number
IL14611300A
Other languages
English (en)
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of IL146113A0 publication Critical patent/IL146113A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
IL14611300A 1999-04-29 2000-04-28 Liposome compositions for improved drug retention IL146113A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13155399P 1999-04-29 1999-04-29
PCT/US2000/011625 WO2000066126A2 (en) 1999-04-29 2000-04-28 Liposome compositions for improved drug retention

Publications (1)

Publication Number Publication Date
IL146113A0 true IL146113A0 (en) 2002-07-25

Family

ID=22449950

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14611300A IL146113A0 (en) 1999-04-29 2000-04-28 Liposome compositions for improved drug retention
IL146113A IL146113A (en) 1999-04-29 2001-10-22 Liposome preparations for improved preservation of drugs

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL146113A IL146113A (en) 1999-04-29 2001-10-22 Liposome preparations for improved preservation of drugs

Country Status (17)

Country Link
EP (1) EP1176962B1 (de)
JP (1) JP2002543134A (de)
KR (1) KR100766753B1 (de)
CN (1) CN1172670C (de)
AT (1) ATE259231T1 (de)
AU (1) AU767474B2 (de)
CA (1) CA2371483A1 (de)
DE (1) DE60008234T2 (de)
DK (1) DK1176962T3 (de)
ES (1) ES2214269T3 (de)
HK (1) HK1044122B (de)
HU (1) HUP0201644A3 (de)
IL (2) IL146113A0 (de)
MX (1) MXPA01010977A (de)
NO (1) NO320629B1 (de)
WO (1) WO2000066126A2 (de)
ZA (1) ZA200108907B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0111279D0 (en) * 2001-05-10 2001-06-27 Nycomed Imaging As Radiolabelled liposomes
AU2002334358B2 (en) * 2001-09-06 2008-02-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem A method for preparing liposome formulations with a predefined release profile
LT3173073T (lt) 2004-05-03 2025-01-10 Ipsen Biopharm Ltd. Liposomos, skirtos vaistų pristatymui
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
WO2006029074A2 (en) * 2004-09-03 2006-03-16 Piedmont Pharmaceuticals, Llc Methods for transmembrane treatment and prevention of otitis media
EP1932517A3 (de) * 2006-12-11 2008-07-16 Universiteit Utrecht Holding B.V. Liposomen beinhaltend Polyphenolderivaten und deren Verfahren zur Nachbeladung
JP5351076B2 (ja) * 2010-02-26 2013-11-27 杏林製薬株式会社 オンライン固相抽出による生体試料液中薬剤成分の定量方法
CN102309448B (zh) * 2010-06-29 2014-07-09 中国人民解放军军事医学科学院毒物药物研究所 一种肺部给药的环丙沙星药用组合物及其制备方法
JP5848511B2 (ja) * 2011-03-29 2016-01-27 株式会社コーセー リポソーム組成物、並びにそれを用いた化粧料、皮膚外用剤及びその製造方法
CN102627642A (zh) * 2012-03-19 2012-08-08 南京洵安医药科技有限公司 莫西沙星金属配合物及其制药用途
US10220095B2 (en) * 2013-03-15 2019-03-05 Taiwan Liposome Company, Ltd Controlled drug release liposome compositions and methods thereof
EP4647126A3 (de) 2015-10-16 2026-02-11 Ipsen Biopharm Ltd. Stabilisierung von pharmazeutischen camptothecinzusammensetzungen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61130239A (ja) * 1984-11-30 1986-06-18 Dai Ichi Seiyaku Co Ltd 複合体
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5227372A (en) * 1990-03-07 1993-07-13 Children's Medical Center Corporation Method for retaining ophthalmological agents in ocular tissues
JPH0447351A (ja) * 1990-06-12 1992-02-17 Nec Corp シングルチップマイクロコンピュータ
AU705718B2 (en) * 1995-05-24 1999-05-27 Alcon Laboratories, Inc. Antibacterial compositions
WO1999055743A1 (en) * 1998-04-28 1999-11-04 Inex Pharmaceuticals Corporation Polyanionic polymers which enhance fusogenicity

Also Published As

Publication number Publication date
WO2000066126A3 (en) 2001-04-05
HK1044122A1 (en) 2002-10-11
HUP0201644A2 (hu) 2002-12-28
DK1176962T3 (da) 2004-06-14
ES2214269T3 (es) 2004-09-16
MXPA01010977A (es) 2002-07-22
EP1176962A2 (de) 2002-02-06
WO2000066126A2 (en) 2000-11-09
NO320629B1 (no) 2006-01-02
EP1176962B1 (de) 2004-02-11
ATE259231T1 (de) 2004-02-15
AU4500600A (en) 2000-11-17
JP2002543134A (ja) 2002-12-17
DE60008234D1 (de) 2004-03-18
HUP0201644A3 (en) 2004-05-28
DE60008234T2 (de) 2004-12-30
ZA200108907B (en) 2002-12-24
NO20015246D0 (no) 2001-10-26
KR20020011978A (ko) 2002-02-09
CA2371483A1 (en) 2000-11-09
HK1044122B (en) 2004-11-26
CN1351495A (zh) 2002-05-29
CN1172670C (zh) 2004-10-27
NO20015246L (no) 2001-12-28
KR100766753B1 (ko) 2007-10-17
AU767474B2 (en) 2003-11-13
IL146113A (en) 2006-07-05

Similar Documents

Publication Publication Date Title
IL146113A0 (en) Liposome compositions for improved drug retention
HUP0202100A3 (en) Novel quinuclidine derivatives, process for their preparation and medicinal compositions containing the same
AU2127697A (en) Method of preparing polynucleotide-carrier complexes for delivery to cells
MY126931A (en) Crystalline monohydrate of tiotropiumbromide, method for producing the same and the use thereof in the production of a medicament
AU4460900A (en) Carrier patch for the delivery of agents to the skin
WO2000007979A3 (en) Compounds and compositions for delivering active agents
AU2274201A (en) Compounds and compositions for delivering active agents
WO2000071125A3 (de) Pharmazeutisches präparat mit dem wirkstoff diamorphin und seine verwendung in einem verfahren zur behandlung der opiatsucht
PT915898E (pt) Forma i cristalina de claritromicina
AU5905400A (en) Methods and compositions for delivery and retention of active agents to lymph nodes
WO2001027099A3 (en) Bicyclic compounds composition and method for stabilizing the same
AU1919900A (en) Process for preparing trifluoroarylaluminum etherates
AU7079700A (en) Improved stable formulations of ace inhibitors, and methods for preparation thereof
EP1167354A3 (de) Racemisches Huperzin A
HUP0203320A3 (en) Indolylpiperidine derivatives and their use as antihistaminic and antiallergic agents, process for their preparation, pharmaceutical compositions containing them
IL150483A0 (en) Liposomes containing an entrapped compound in supersaturated solution
AU2420001A (en) Methods and compositions for the treatment of pain
HUP0105028A3 (en) Compositions having improved stability and process for their preparation
AU2001256568A1 (en) New compounds having anticancer activity: process for their preparation and pharmaceutical compositions containing them
AU2001258106A1 (en) Lipid carrier compositions for improved drug retention
PT1181300E (pt) Derivados 6-o-carbamato de cetolido
HUP0203161A3 (en) Benzamidine derivatives, process for their preparation and pharmaceutical compositions containing them and their use
WO2001040241A3 (en) 6-o-alkyl-2-nor-2-substituted ketolide derivatives
HUP0203210A3 (en) Substituted isoquinoline derivatives and their use as anticonvulsants, process for their preparation and pharmaceutical compositions containing them
AU2129800A (en) Improved process for the preparation of benzenesulfonylureas as oral hypoglycemic agents of the second generation

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed